Merck News (NYSE:MRK)

DateTimeSource
Headline
01/18/20179:00AMBWMerck Foundation Grant Expands Project ECHO® in Vietnam and India
Project Increases Access to Specialty Care for Complex, Chronic Conditions The Merck Foundation (Foundation) and the Extension for Community Healthcare Outcomes (ECHO) Institute™ at the University of New Mexico Health Sciences Center announced today that the Foundation has provided a grant of $7 million over five years... More...>>
01/12/20173:03AMDJNHealth Stocks Fall as Trump Slams Industry -- WSJ
By Akane Otani and Riva Gold Major U.S. stock indexes shook off a slide in health-care shares and closed higher Wednesday. In a choppy session, stocks rose heading into President-elect Donald Trump's first news conference since the election, then dipped into negative territory during the event before recovering in... More...>>
01/10/20174:06PMBWMerck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination wit...
Submission Based on Data from KEYNOTE-021 Trial, Cohort G, Which Enrolled Patients Regardless of PD-L1 Expression Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application... More...>>
01/09/20178:00AMBWIncyte & Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembroli...
Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada... More...>>
01/06/20178:00AMBWMerck to Participate at the 35th Annual J.P. Morgan Healthcare Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on... More...>>
01/04/20173:05PMDJNPennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate--Update
By Peter Loftus A federal judge ordered Pennsylvania's corrections department to provide costly new antiviral drugs to an inmate infected with hepatitis C, and rebuked the state for restricting inmates' access to the drugs. Hepatitis C is an epidemic in prisons, but state corrections departments have treated... More...>>
01/04/201711:32AMDJNPennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate
By Peter Loftus A federal judge ordered Pennsylvania's corrections department to provide costly new antiviral drugs to an inmate infected with hepatitis C, and rebuked the state for restricting inmates' access to the drugs. Hepatitis C is an epidemic in prisons, but state corrections departments have treated... More...>>
01/03/20176:45AMBWMerck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 2. During the call, company executives will provide an overview of Merck’s performance for... More...>>
12/28/20163:02AMDJNAhead of the Tape: Trump Gives 'Dogs of the Dow' Pause -- WSJ
By Steven Russolillo The "Dogs of the Dow" have suddenly lost their bite as the year winds down. Yes, one of Wall Street's classic investing strategies is on pace to beat the Dow Jones Industrial Average for a fourth year in a row. But the outperformance has shrunk since Donald Trump's election victory... More...>>
12/27/20164:28PMDJNDonald Trump Dogs Dow Strategy -- Ahead of the Tape
By Steven Russolillo The "Dogs of the Dow" have suddenly lost their bite as the year winds down. Yes, one of Wall Street's classic investing strategies is on pace to beat the Dow Jones Industrial Average for a fourth year in a row. But the outperformance has shrunk since Donald Trump's election victory... More...>>
12/19/20165:52PMDJNBiogen Names New CEO -- Update
By Ezequiel Minaya Biogen Inc. said Monday it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company's commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this year his intention to step down after his replacement was found... More...>>
12/19/20167:00AMBWKEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced No...
KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients... More...>>
12/16/20167:26AMBWEuropean Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients w...
Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLC Merck (NYSE:MRK), known as MSD outside the United... More...>>
12/15/20166:40PMDJNGilead Sciences Ordered to Pay $2.5 Billion in Damages to Merck & Co. -- Update
By Jonathan D. Rockoff A federal jury in Delaware on Thursday ordered Gilead Sciences Inc. to pay $2.5 billion in damages to Merck & Co. for infringing its patents in developing hepatitis C drugs. The patent-infringement decision, issued by a jury in a U.S. District Court in Delaware, involved two Gilead drugs that... More...>>
12/15/20166:36PMDJNGilead Sciences Ordered to Pay $2.5 Billion in Damages to Merck & Co.
By Jonathan D. Rockoff A federal jury in Delaware on Thursday ordered Gilead Sciences Inc. to pay $2.5 billion in damages to Merck & Co. for infringing its patents in developing hepatitis C drugs. The patent-infringement decision, issued by a jury in a U.S. District Court in Delaware, involved two Gilead drugs that... More...>>
12/15/20166:05PMDJNCourt Orders Gilead to Pay Merck $2.54 Billion in Patent Case -Reuters
A Delaware jury ordered Gilead Sciences Inc. (GILD) to pay Merck & Co. (MRK) $2.54 billion of royalties in a patent lawsuit, Reuters reported Thursday. The jury found a Merck patent on hepatitis C drugs was valid, the report said. Full story at http://www.reuters.com/article/us-gilead-sciences-merck-co-verdict-idUSKBN1442U9... More...>>
12/12/20167:00AMPRNUSInterim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® ...
Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 San Antonio Breast Cancer Symposium PR Newswire KENILWORTH, N.J. and WOODCLIFF LAKE, N.J., Dec. 12, 2016... More...>>
12/07/20163:00PMPRNCANouvelles données de l'étude d'observation la plus vaste en cours sur l'efficacité du vaccin contre le zona présentées l...
Nouvelles données de l'étude d'observation la plus vaste en cours sur l'efficacité du vaccin contre le zona présentées lors de la Conférence canadienne sur l'immunisation Canada NewsWire KIRKLAND, QC, le 7 déc. 2016 KIRKLAND, QC, le 7 déc. 2016 /CNW Telbec/ - Merck (NYSE: MRK), connue... More...>>
12/07/20162:56PMPRNCANew Data from the Largest Ongoing Observational Study Assessing Shingles Vaccine Effectiveness Presented at Canadian Immuniza...
New Data from the Largest Ongoing Observational Study Assessing Shingles Vaccine Effectiveness Presented at Canadian Immunization Conference Canada NewsWire KIRKLAND, QC, Dec. 7, 2016 KIRKLAND, QC, Dec. 7, 2016 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside Canada and the United States, today announced new data... More...>>
12/07/20161:09PMDJNMARKET SNAPSHOT: Stock Market Shakes Off Trump-inspired Health-care Drop To Set Intraday Records
By Mark DeCambre and Victor Reklaitis, MarketWatch The IBB is on track for its worst daily drop since the U.K.'s vote to exit from the European Union U.S. stocks were on a record run in Wednesday afternoon trade. The Dow industrials, S&P 500 and small-cap focused Russell 2000 all rose to all-time highs in intraday... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20170118 20:08:23